Maria de Fátima Dias Gaui

Instituição:

Universidade Federal do Rio de Janeiro

Centro:

Centro de Ciências da Saúde

Unidade:

Faculdade de Medicina

Departamento:

Departamento de Clínica Médica/FM

ORCID:

https://orcid.org/0000-0003-3053-839X


Formação:

  • Universidade Federal do Rio de Janeiro

    Medicina (Anatomia Patológica) | Doutorado | 2018 - Agora

  • Universidade Federal do Rio de Janeiro

    Clínica Médica | Mestrado | 2004 - 2006

  • Instituto Nacional de Câncer

    | Especialização - Residência medica | 1988 - 1991

  • Universidade Federal do Rio de Janeiro

    | Especialização - Residência medica | 1985 - 1988
Laboratórios:
Nenhum laboratório cadastrado
Nuvens de Palavras:
Artigos:

(63.64% artigos com DOI)

Titulo DOI Ano
Epstein-Barr virus in gastric cancer and association with 30 bp del-latent membrane protein 1 polymorphism 10.1590/1806-9282.20221571 2023
Spirituality in Oncology - a consensus by the Brazilian Society of Clinical Oncology 2023
Programmed cell death protein 1 is a marker for neoadjuvant chemotherapy response in triple-negative breast cancer 10.1590/1806-9282.20230276 2023
RNA Expression Classifiers from a Model of Breast Epithelial Cell Organization to Predict Pathological Complete Response in Triple Negative Breast Cancer 10.26502/acbr.50170170 2021
Clinicopathologic profile of breast cancer patients treated with neoadjuvant chemotherapy at HUCFF/UFRJ 10.29289/2594539420200076 2021
Analysis on complete pathological response and estimated survival among breast cancer patients undergoing neoadjuvant chemotherapy in a private institution in the state of Rio de Janeiro 10.5935/2526-8732.20210026 2021
Invasive lobular breast carcinoma metastatic to the colon: a case report of a rare condition and its challenges 10.5935/2526-8732.202000 2020
Outcome of Patients With Breast Cancer Treated in a Private Health Care Institution in Brazil 10.1200/jgo.17.00143 2018
15 anos de morbidade hospitalar do carcinoma medular da tireoide a partir do Registro Hospitalar de Câncer no Brasil 2018
A Phase II Study of Second-Line Neoadjuvant Chemotherapy With Capecitabine and Radiation Therapy for Anthracycline-Resistant Locally Advanced Breast Cancer 2007
Intensified ABVP Chemotherapy for the primary treatment of hodgkin´s disease 2002
Eventos:

(0.00% eventos com DOI)

Titulo DOI Ano
Second-line neoadjuvant chemotherapy with capecitabine and radiotherapy for locally advanced breast cancer failing anthracyclines 2004
Second-line neoadjuvant (NEO) with cisplatin (C) 5Fluorouracil (5FU) and Radiotherapy for locally advanced breast cancer (LABC) refractory to anthracyclines: Evaluation after a long-term follow up. 2004
Cisplatinum (C), 5Fluoruracil (FU) and Radiotherapy (XRT) Neoadjuvant (NAJ) for locallly Advanced Breast Cancer (LABC), Resistant to Anthracyclines Proc . Am. Soc. Clin.Oncol. Vol 16 1997. 1997
Publicações:
Minha Rede: